InChIKey	BCFGMOOMADDAQU-UHFFFAOYSA-N
Compound Name	Lapatinib
Canonical SMILES	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1
Clinical Status	Clinical Multi-Target
Targets (Human+Pathogen)	6
Pfam Stratification	Cross-Family
Avg pChEMBL	6.96
Source	BindingDB;ChEMBL;TTD_MultiTarget

DrugBank ID	DB01259
Drug Name	Lapatinib
CAS Number	231277-92-2
Groups	approved investigational
ATC Codes	L01EH01
Description	Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapati...

---

Categories: Antineoplastic Agents Antineoplastic and Immunomodulating Agents Cytochrome P-450 CYP2C19 Substrates Cytochrome P-450 CYP2C8 Inhibitors Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) Cytochrome P-450 CYP2C8 Substrates Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Inhibitors Cytochrome P-450 CYP3A4 Inhibitors (weak) Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 CYP3A5 Substrates Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Enzyme Inhibitors Hepatotoxic Agents Heterocyclic Compounds, Fused-Ring Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors Kinase Inhibitor P-glycoprotein inhibitors Potential QTc-Prolonging Agents Protein Kinase Inhibitors QTc Prolonging Agents Quinazolines Tyrosine Kinase Inhibitors

---

Cross-references: BindingDB: 5445 ChEBI: 49603 CHEMBL554 ChemSpider: 181006 Drugs Product Database (DPD): 20463 D04024 PDB: FMM PharmGKB: PA152241907 PubChem:208908 PubChem:46507141 RxCUI: 480167 Therapeutic Targets Database: DCL000344 Wikipedia: Lapatinib ZINC: ZINC000001550477